Active Ingredient Matching

The foundational mapping layer that links proprietary drug names to a standardized clinical drug vocabulary. RxNorm assigns a unique concept identifier (RXCUI) to every active ingredient, dose form, and strength combination.

• Resolves Tylenol and acetaminophen to the same base ingredient
• Enables cross-system interoperability between pharmacy benefit managers and EHRs
• Maintains semantic relationships: has_ingredient, has_tradename, consists_of

The primary clinical safety function of active ingredient matching. When a provider orders ibuprofen for a patient already taking Motrin, the system flags a Duplicate Therapy Alert before administration.

• Compares new orders against the active medication list in real time
• Prevents unintentional overdose from combination products like Excedrin (acetaminophen + aspirin + caffeine)
• Reduces alert fatigue by suppressing alerts for intentional duplicate therapy (e.g., tapering protocols)

Advanced NLP techniques that map free-text medication mentions to structured ingredient codes. ClinicalBERT and other domain-adapted models disambiguate ambiguous drug names in narrative notes.

• Resolves 'ASA' to acetylsalicylic acid (aspirin)
• Handles misspellings and regional brand names like 'paracetamol' vs. 'acetaminophen'
• Uses confidence thresholding to route low-certainty matches for human review

Extends ingredient matching beyond duplicate detection to predict hypersensitivity reactions. The system identifies structural similarity between a documented allergen and a newly prescribed drug.

• Flags cephalosporins for patients with documented penicillin allergy due to beta-lactam ring cross-reactivity
• References Structured Product Labeling (SPL) data for excipient and preservative ingredients
• Integrates with Drug-Drug Interaction engines for comprehensive safety screening

Computes cumulative exposure when multiple products contain the same active ingredient. Critical for acetaminophen toxicity prevention, where the maximum daily dose is 4,000mg.

• Detects hidden sources: Vicodin (hydrocodone + acetaminophen) + OTC Tylenol PM
• Normalizes disparate strength units (mg, mcg, IU) for accurate summation
• Triggers renal dose adjustment alerts when cumulative dose exceeds eGFR-based thresholds

Leverages ingredient matching to suggest therapeutically equivalent alternatives when a prescribed drug is not on a payer's formulary. The system identifies generic equivalents and therapeutic alternatives within the same pharmacologic class.

• Maps Lipitor to atorvastatin for automatic generic substitution
• Suggests lansoprazole when omeprazole is preferred on formulary
• Considers dose form equivalence to ensure clinically appropriate substitution

A clinical decision support notification triggered when a new medication order is placed for a drug that is therapeutically equivalent or identical to an existing active order. Without robust active ingredient matching, a system may fail to recognize that a branded drug and its generic equivalent are duplicates, posing a significant risk of overdose. The alert's precision is directly dependent on the underlying ingredient resolution algorithm.

A type of medication discrepancy where a clinically indicated drug that a patient was taking prior to a care transition is unintentionally not prescribed on the new medication orders. Active ingredient matching prevents omission errors by identifying that a patient's home medication is available in the hospital formulary under a different brand name, ensuring the therapy is continued rather than mistakenly omitted.

The algorithmic check that identifies structural or pharmacologic similarities between a newly prescribed drug and a documented patient allergy. This process depends on active ingredient matching to resolve the chemical class of a drug. For example, a patient allergic to 'Bactrim' must be flagged for an allergy to any product containing sulfamethoxazole or trimethoprim, regardless of the brand name.

The computational process of converting disparate representations of medication strength and frequency into a standardized, comparable format. After active ingredient matching resolves two products to the same base compound, dose normalization calculates the cumulative daily exposure. This detects whether a patient is receiving a duplicate therapy at a combined supratherapeutic dose.